Elicio Q2 net loss $10.6M; IDMC positive for ELI-002 Phase 2; DFS readout Q4 2025

Elicio Therapeutics, Inc.

2025-Q2 EPS reported -$1.50 vs consensus -$0.70 ▼ miss (-114.7%)

IDMC recommended continue ELI-002 Phase 2 pancreatic study without modification; final DFS analysis expected Q4 2025.
Net loss $10.6M in Q2 2025 vs $7.2M in Q2 2024; R&D expense decreased to $7.0M.
Cash $22.1M at June 30, 2025; secured $10M non-dilutive financing in Q2 2025.
Company expects cash to fund operations into Q1 2026, beyond Phase 2 final analysis.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.